prophylaxis in comparison with CsA alone, in patients receiving antithymocyte globulin (ATG)-based RIC allo-SCT from an HLA-MUD.
This is a retrospective analysis of two groups of consecutive patients having the same demographic and transplant procedure characteristics (except for GVHD prophylaxis, Table 1 ), who were treated in a single institution (CHU de Nantes, Nantes, France). Eligibility criteria for RIC allo-SCT are detailed elsewhere. 3, 4 Written informed consent was obtained from each patient and donor. The study was carried out according to institutional guidelines.
The first group of patients from this series (n ¼ 19; group I) received CsA alone for GVHD prophylaxis. The next group of patients (n ¼ 16; group II) received CsA and Table 1 Patients and donors characteristics and analysis of risk factors for acute GVHD according to GVHD prophylaxis regimen 10 Supportive care and antimicrobial prophylaxis were previously reported.
MMF. CsA was administered at a dose of 3 mg/kg/day by continuous i.v. infusion starting from day 2, and was changed to a twice daily oral dose as soon as could be tolerated. CsA doses were adjusted to achieve blood levels between 150 and 300 ng/ml and to prevent renal dysfunction. MMF was administered at a fixed oral dose of 1 g Â 2/day, starting usually from day 0 after allo-SCT. No treatment adjustment was carried out for MMF. As per protocol, MMF was tapered over 4 weeks starting from day 60, and CsA from day 90, if no GVHD appeared. It is noteworthy that during the whole study period, supportive care was comparable between patients from groups I and II. Of note, CMV infection management was similar between both groups. aGVHD and chronic GVHD (cGVHD) was defined according to the Seattle Standard Criteria. Detailed statistical methods are described elsewhere. 3, 5 In this series, the first 19 patients received CsA alone for GVHD prophylaxis. However, in an attempt to decrease the incidence of aGVHD in this subgroup of high-risk patients receiving allografts from HLA-MUD, we carried out a pilot study to assess the benefit of MMF use in addition to CsA for GVHD prophylaxis. Thus, the following 16 patients received MMF in addition to CsA. Three patients from this series did not engraft (early disease recurrence) and were not evaluable for aGVHD. No significant or major toxicities were associated with the administration of MMF, and this was comparable with other published reports. 6 The cumulative incidence of grade 2-4 aGVHD at day 100 was 67% (n ¼ 12; 95%CI, 45-89%) in patients receiving 'CsA alone' as compared with 57% (95%CI, 31-83%) in those receiving the 'CsA þ MMF' combination (P ¼ NS). However, the cumulative incidence of grade 3-4 aGVHD was significantly lower in the 'CsA þ MMF' group as compared with that in the 'CsA' group (n ¼ 2; 14% vs n ¼ 10; 56%, respectively; P ¼ 0.02; Figure 1a ). The median time to onset of grade 2-4 aGVHD was 37 (range, 17-58) days after allo-SCT. In patients evaluable for cGVHD (n ¼ 24; 69%), eight patients from this series (three patients in the CsA group and five patients in the CsA þ MMF group) experienced limited (n ¼ 2) or extensive cGVHD (n ¼ 6). However, because of the limited number of patients in each group, we did not perform any statistical comparisons in terms of cGVHD. Overall, 16 deaths were observed in this cohort: 3 cases because of disease progression/relapse and 13 cases because of nonrelapse mortality causes. Four deaths were attributed to refractory aGVHD in the 'CsA' group vs none in the 'CsA þ MMF' group. The other causes of death included four cases of multiorgan failure (with aGVHD symptoms), all in the CsA group, two cases of refractory cGVHD and infection, and three other various causes for an overall incidence of nonrelapse mortality of 37%. After a median follow-up of 19.5 (range, 9-93) months for surviving patients (in the whole study population, median follow-up was 14.6 months in the 'CsA þ MMF' group vs 9.9 months in the 'CsA' group, P ¼ NS), the Kaplan-Meier estimate of disease-free survival was 51% at 1 year after transplantation. The 1-year OS was significantly higher in the 'CsA þ MMF' group as compared with that in the CsA group (81 vs 47%; P ¼ 0.03; Figure 1b) . In a Cox multivariate analysis, taking into account pre-transplantation characteristics, the GVHD prophylaxis regimen (CsA þ MMF) was the strongest factor associated with a significantly improved OS (RR, 0.29; 95% confidence interval (CI), 0.09 to 0.91; P ¼ 0.03).
Initially, it was not a common practice in our centre to include MMF for GVHD prophylaxis, because we felt that the use of ATG would be sufficient to control GVHD even in patients receiving a transplant from an HLA-MUD. This pilot study suggests that adjunction of MMF to CsA is feasible, and can apparently result in a significant reduction in the grade 3-4 aGVHD rate after ATG-based RIC allo-SCT for high-risk patients receiving a transplant from an HLA-MUD. As a matter of fact, besides the GVHD prophylaxis regimen, and because of the relatively low number of patients, some other risk factors might have accounted for the higher incidence of severe aGVHD in the 'CsA alone' group. Nevertheless, results from this study are in contrast to our findings using a similar RIC regimen, but with HLA-identical sibling donors, in whom we were unable to show a benefit for the 'CsA þ MMF' combination in comparison with 'CsA alone'. 7 However, such a discrepancy can explain the higher risk for severe aGVHD when using a graft from an HLA-MUD. From a practical standpoint, in this study, we did not carry out any dose adjustment of MMF blood levels. However, some authors have shown that a therapeutic monitoring of MMF concentrations seems to be necessary for the most effective use of MMF. 8 The rapidly increasing use in elderly and highrisk patients and the evolving nature of RIC allo-SCT emphasize the need for renewed clinical research of GVHD prophylaxis, which may have a significant impact on the probability of a favourable outcome. We at present are prospectively testing the 'CsA þ MMF' combination in a fludarabine-BU-ATG RIC allo-SCT setting in an HLA-MUD.
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